EGFR and urothelial carcinoma: MUC1-CAR-T cells exhibited selective cytotoxicity against MUC1-positive BC organoids (Yu et al., 2021), while combining decitabine with EGFR- or CD44v6-CAR-T cells enhanced cytotoxicity against urothelial carcinoma cell lines (Grunewald et al., 2021).